Search

MediciNova Inc

Geschlossen

BrancheGesundheitswesen

1.54 1.32

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.45

Max

1.56

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.9B

-4.9B

Verkäufe

271K

458K

EPS

-0.05

Gewinnspanne

-1,068,366.946

Angestellte

6

EBITDA

5.1K

-2.5M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+422.88% upside

Dividenden

By Acuity

Nächstes Ergebnis

10. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

65M

Vorheriger Eröffnungskurs

0.22

Vorheriger Schlusskurs

1.54

Nachrichtenstimmung

By Acuity

50%

50%

150 / 340 Ranking in Healthcare

MediciNova Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Aug. 2026, 20:02 UTC

MediciNova Inc shares are higher today, continuing a strong upward trend since Friday's close. The stock remains near the upper end of its one-month range.

21. Aug. 2026, 19:56 UTC

MediciNova Inc's shares are higher today, continuing a positive trend. The stock is trading above its 20-day moving average amid gains in the cryptocurrency sector.

20. Aug. 2026, 19:16 UTC

MediciNova Inc. shares are lower today, having previously declined significantly before recovering. The price remains above its 20-day moving average.

18. Aug. 2026, 19:56 UTC

MediciNova Inc shares are higher, reflecting positive market momentum. The stock remains above its 20-day moving average and near the upper end of its one-month range.

17. Aug. 2026, 19:56 UTC

News

MediciNova shares are higher as the company reported earnings of -$0.05 per share, surpassing estimates and generating $0.46 million in revenue.

13. Aug. 2026, 19:26 UTC

MediciNova Inc shares are lower amid broader market pressure from rising jobless claims and stabilizing inflation indicators. The stock trades near its one-month range low.

12. Aug. 2026, 19:56 UTC

MediciNova Inc. shares are trading roughly flat with no specific news identified, remaining near the lower end of their one-month trading range.

11. Aug. 2026, 20:06 UTC

MediciNova Inc. shares are roughly flat, showing little movement since Monday's close and positioned near the lower end of their one-month trading range.

10. Aug. 2026, 19:46 UTC

MediciNova Inc shares are lower today, continuing a downward trend since Friday. Broader market sentiment is affected by recent U.S. employment data.

7. Aug. 2026, 19:46 UTC

MediciNova Inc. shares are higher today, recovering from earlier losses. The stock is trading around the middle of its one-month range.

6. Aug. 2026, 20:13 UTC

MediciNova Inc shares are higher in after-market trading, reflecting strength since Thursday's close amid rising U.S. Treasury yields and a hawkish Fed outlook.

4. Aug. 2026, 19:36 UTC

MediciNova Inc. shares are trading roughly flat amid broader market reactions to a decline in U.S. core factory orders and ongoing strength in AI sectors.

3. Aug. 2026, 20:06 UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

31. Juli 2026, 19:56 UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

30. Juli 2026, 20:51 UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

29. Juli 2026, 20:09 UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

28. Juli 2026, 18:46 UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

27. Juli 2026, 19:06 UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

24. Juli 2026, 23:02 UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

23. Juli 2026, 20:06 UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

21. Juli 2026, 19:21 UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Peer-Vergleich

Kursveränderung

MediciNova Inc Prognose

Kursziel

By TipRanks

422.88% Vorteil

12-Monats-Prognose

Durchschnitt 8 USD  422.88%

Hoch 10 USD

Tief 6 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für MediciNova Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Stimmung

By Acuity

150 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
help-icon Live chat